clinical trial · NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CP-CML
Chronic Myeloid LeukemiaCMLCML, Chronic PhaseolverembatinibBosutinib
brief summary
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
started
Feb 5, 2024
primary completion
Dec 1, 2025
completion
Feb 1, 2026
last updated
Jun 3, 2025
detailed description
The hypothesis suggests that in Part A, olverembatinib leads to a higher MMR rate compared to bosutinib in CP-CML patients without the T315I mutation; and in Part B, olverembatinib can provide therapeutic benefits to CP-CML patients with the T315I mutation.
official title
This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol